AAAAAA
Results: 1-25/28
Authors:
Logothetis, CJ
Wu, KK
Finn, LD
Daliani, D
Figg, W
Ghaddar, H
Gutterman, JU
Citation: Cj. Logothetis et al., Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer, CLIN CANC R, 7(5), 2001, pp. 1198-1203
Authors:
Newman, RA
Yang, J
Finlay, MRV
Cabral, F
Vourloumis, D
Stephens, LC
Troncoso, P
Wu, XB
Logothetis, CJ
Nicolaou, KC
Navone, NM
Citation: Ra. Newman et al., Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts, CANC CHEMOT, 48(4), 2001, pp. 319-326
Authors:
Tu, SM
Millikan, RE
Mengistu, B
Delpassand, ES
Amato, RJ
Pagliaro, LC
Daliani, D
Papandreou, CN
Smith, TL
Kim, J
Podoloff, DA
Logothetis, CJ
Citation: Sm. Tu et al., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial, LANCET, 357(9253), 2001, pp. 336-341
Authors:
Merritt, JA
Roth, JA
Logothetis, CJ
Citation: Ja. Merritt et al., Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies, SEMIN ONCOL, 28(5), 2001, pp. 105-114
Authors:
Logothetis, CJ
Citation: Cj. Logothetis, Docetaxel in the treatment of prostate cancer: Opportunities for combination regimens and challenges to development, SEMIN ONCOL, 28(4), 2001, pp. 1-2
Authors:
Yang, J
Fizazi, K
Peleg, S
Sikes, CR
Raymond, AK
Jamal, N
Hu, M
Olive, M
Martinez, LA
Wood, CG
Logothetis, CJ
Karsenty, G
Navone, NM
Citation: J. Yang et al., Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway, CANCER RES, 61(14), 2001, pp. 5652-5659
Authors:
Fizazi, K
Amato, RJ
Beuzeboc, P
Petit, N
Bouhour, D
Thiss, A
Rebischung, C
Chevreau, C
Logothetis, CJ
Droz, JP
Citation: K. Fizazi et al., Germ cell tumors in patients infected by the human immunodeficiency virus, CANCER, 92(6), 2001, pp. 1460-1467
Authors:
Millikan, RE
Plunkett, WK
Smith, TL
Williams, DL
Logothetis, CJ
Citation: Re. Millikan et al., Gemcitabine modulation of alkylator therapy - A Phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin, CANCER, 92(1), 2001, pp. 194-199
Authors:
Navone, NM
Rodriguez-Vargas, MD
Benedict, WF
Troncoso, P
McDonnell, TJ
Zhou, JH
Luthra, R
Logothetis, CJ
Citation: Nm. Navone et al., TabBO: A model reflecting common molecular features of androgen-independent prostate cancer, CLIN CANC R, 6(3), 2000, pp. 1190-1197
Authors:
Ozen, M
Hopwood, VL
Balbay, MD
Johnston, DA
Babaian, RJ
Logothetis, CJ
Von Eschenbach, AC
Pathak, S
Citation: M. Ozen et al., Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters, INT J ONCOL, 17(1), 2000, pp. 113-117
Authors:
Pettaway, CA
Pisters, LL
Troncoso, P
Slaton, J
Finn, L
Kamoi, K
Logothetis, CJ
Citation: Ca. Pettaway et al., Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results, J CL ONCOL, 18(5), 2000, pp. 1050-1057
Authors:
Pisters, LL
Pettaway, CA
Hossan, E
Evans, R
Steiner, MS
Wood, CG
Troncoso, P
McDonnell, TJ
Fenstenmacher, MJ
Logothetis, CJ
Citation: Ll. Pisters et al., Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results, PROSTATE C, 2, 1999, pp. S27-S27
Authors:
Amato, RJ
Bui, C
Logothetis, CJ
Citation: Rj. Amato et al., Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate, PROSTATE C, 2(2), 1999, pp. 83-87
Authors:
Park, DS
Prow, DM
Amato, RJ
Logothetis, CJ
Citation: Ds. Park et al., Management consideration in nonpulmonary visceral metastatic seminoma of testis, J KOR MED S, 14(4), 1999, pp. 431-437
Authors:
Luo, WP
Tapolsky, M
Earley, K
Wood, CG
Wilson, DR
Logothetis, CJ
Lin, SH
Citation: Wp. Luo et al., Tumor-suppressive activity of CD66a in prostate cancer, CANC GENE T, 6(4), 1999, pp. 313-321
Authors:
Logothetis, CJ
Millikan, R
Citation: Cj. Logothetis et R. Millikan, Update: NCCN practice guidelines for the treatment of prostate cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 118-132
Authors:
Park, DS
Prow, DM
Amato, RJ
Ro, JY
Logothetis, CJ
Citation: Ds. Park et al., Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era, YONSEI MED, 40(2), 1999, pp. 137-143
Authors:
Lin, SH
Pu, YS
Luo, WP
Wang, Y
Logothetis, CJ
Citation: Sh. Lin et al., Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancermodel, ANTICANC R, 19(1A), 1999, pp. 337-340
Authors:
Kim, J
Logothetis, CJ
Citation: J. Kim et Cj. Logothetis, Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma, UROL CLIN N, 26(2), 1999, pp. 281
Authors:
Logothetis, CJ
Citation: Cj. Logothetis, Concluding comments, SEMIN ONCOL, 26(5), 1999, pp. 68-68
Authors:
Logothetis, CJ
Citation: Cj. Logothetis, A therapeutically relevant framework for the classification of human prostate cancer - Introduction, SEMIN ONCOL, 26(4), 1999, pp. 369-374
Authors:
Logothetis, CJ
Citation: Cj. Logothetis, Introduction: Prostate cancer, SEMIN ONCOL, 26(2), 1999, pp. 139-139
Authors:
Ozen, M
Hopwood, VL
Johnston, DA
Babaian, RJ
Logothetis, CJ
von Eschenbach, AC
Pathak, S
Citation: M. Ozen et al., Aneuploidy index in blood: A potential marker for early onset, androgen response, and metastasis in human prostate cancer, UROLOGY, 53(2), 1999, pp. 381-385
Authors:
Navone, NM
Labate, ME
Troncoso, P
Pisters, LL
Conti, CJ
Von Eschenbach, AC
Logothetis, CJ
Citation: Nm. Navone et al., p53 mutations in prostate cancer bone metastases suggest that selected p53mutants in the primary site define foci with metastatic potential, J UROL, 161(1), 1999, pp. 304-308
Authors:
Horti, J
Dixon, SC
Logothetis, CJ
Guo, Y
Reed, E
Figg, WD
Citation: J. Horti et al., Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor, BR J CANC, 79(9-10), 1999, pp. 1588-1593